DPP4 and cholangiocarcinoma: In conclusion, in this study using nationwide data from three Scandinavian countries and sulfonylureas as the comparator, neither use of DPP4 inhibitors nor use of GLP-1-receptor agonists was associated with a significantly increased risk of cholangiocarcinoma.